← Back to Search

Chemotherapy

Zevalin + Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma (Zevalin Trial)

Phase 2
Waitlist Available
Led By Ahmed Galal, MD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance 0-2
Age >=18 to <=70 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Zevalin Trial Summary

This trial is testing a new cancer treatment that combines a targeted radiation therapy with high-dose chemotherapy and stem cell transplantation.

Who is the study for?
Adults aged 18-70 with advanced stage Non-Hodgkin's lymphoma, specifically Follicular Lymphoma or other types expressing CD20 antigen. Participants must be in relatively good health (ECOG 0-2), have collected enough stem cells for transplant, and not be pregnant or breastfeeding. Exclusions include severe lung function defects, CNS lymphoma, ongoing infections, prior radioimmunotherapy or significant organ dysfunction.Check my eligibility
What is being tested?
The trial is testing the combination of Zevalin (a radioactive antibody) with BEAM chemotherapy followed by a stem cell transplant in patients whose Non-Hodgkin's lymphoma has returned or resisted treatment. The goal is to see if this approach is safe and effective at treating the disease.See study design
What are the potential side effects?
Potential side effects may include reactions related to radiation exposure from Zevalin such as nausea and lowered blood counts leading to increased infection risk. Chemotherapy can cause hair loss, fatigue, mouth sores and increase infection risk due to low blood cell counts.

Zevalin Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am able to get out of my bed or chair and move around.
Select...
I am between 18 and 70 years old.
Select...
My lymphoma is advanced, has returned or didn't respond to treatment, and tests positive for CD20.
Select...
I have had a specific type of stem cell collected for treatment.

Zevalin Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall response rate
Secondary outcome measures
Survival Data, adverse events, molecular response

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor
392 Previous Clinical Trials
984,569 Total Patients Enrolled
McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER
440 Previous Clinical Trials
159,078 Total Patients Enrolled
Ahmed Galal, MDPrincipal InvestigatorMcGill University Health Center, Royal Victoria Hospital
1 Previous Clinical Trials

Media Library

BEAM (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00438581 — Phase 2
Non-Hodgkin's Lymphoma Research Study Groups:
Non-Hodgkin's Lymphoma Clinical Trial 2023: BEAM Highlights & Side Effects. Trial Name: NCT00438581 — Phase 2
BEAM (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00438581 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this study still open?

"As per clinicaltrials.gov, this trial is not presently seeking participants; it was initially posted in March 2007 and most recently edited several weeks ago. However, there are currently 1778 other studies looking for enrolment right now."

Answered by AI

Does this research open its doors to elderly participants?

"The requirements to participate in this trial dictate that individuals must be between the age of 18 and 70."

Answered by AI

Who is authorized to participate in this investigation?

"40 individuals between the ages of 18 and 70, who are presently suffering from lymphoma may be eligible for enrolment in this trial. Further qualifications include being within an Eastern Cooperative Oncology Group (ECOG) performance score range of 0 to 2."

Answered by AI

Has this medicine attained sanction from the Federal Drug Administration?

"The safety of this treatment has been assessed as a 2, since Phase 2 trial data only exists to suggest its security but not yet its effectiveness."

Answered by AI
~2 spots leftby Mar 2025